VALUE OF THE -2PROPSA INDEX AND THE PROSTATE HEALTH INDEX IN PATIENTS WITH PROSTATE CANCER: REVIEW OF LITERATURE AND DATA OF RUSSIAN PROSPECTIVE STUDY


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The article presents the analysis of the fundamental studies on the -2proPSA and prostate health index (PHI) and the determination of their field ofuse in patients with prostate cancer (PCa). The main aspects of use of the new markers studied include improvement of detection of prostate cancer, increase of specificity and reduction of the number of unnecessary biopsies, identification of aggressive forms of prostate cancer, as well as determination of the progression of the disease. The results of numerous studies, as well as preliminary data of Russian study on the assessment of new indicators are promising and today allow to recommend the use of the test to determine the values of the -2proPSA and prostate health index (PHI) in routine urological practice.

Full Text

Restricted Access

About the authors

K. B Kolontarev

SBEI HPE «Moscow State Medical Stomatological University n.a. A.I. Evdokimov»

Email: kolontarev@me.com
PhD in Medical Sciences, Teaching Assistant at the Department of Urology

A. V Govorov

SBEI HPE «Moscow State Medical Stomatological University n.a. A.I. Evdokimov»

Department of Urology

T. A. Osipova

Scientific center «EfiS»

A. V Sidorenkov

SBEI HPE «Moscow State Medical Stomatological University n.a. A.I. Evdokimov»

Department of Urology

D. Yu. Pushkar

SBEI HPE «Moscow State Medical Stomatological University n.a. A.I. Evdokimov»

Department of Urology

References

  1. Sensabaugh G.F. Isolation and characterization of a semen-specific protein from human seminal plasma: a potential new marker for semen identification. J. Forensic. Sci. 1978;23:105-115.
  2. Wang M.C., Valenzuela L.A., Murphy G.P. et al. Puplication of a human prostate specific antigen. J. Urol. 1996;155:1705.
  3. Wang M.C., Kuriyama M., Papsidero L.D. et al. Prostate antigen of human cancer patients. In: Methods in cancer research. H. Busch, L. Yeoman, eds. N.Y., 1982. P. 179-197.
  4. Лоран О.Б., Пушкарь Д.Ю., Франк Г.А. Простат-специфический антиген и морфологическая характеристика рака предстательной железы. Руководство для врачей. М., 1999.
  5. Коган М.И., Якимчук Т.П., Медведев В.Л. Целесообразность включения биопсии переходной зоны и семенных пузырьков в схему многофокусной биопсии предстательной железы под трансектальным ультразвуковым контролем. Материалы пленума правления Российского общества урологов. Омск, 1999. С. 70-71.
  6. Lilja H. A kaffikrein-like serine protease in prostatic fluid cleaves the predominant seminal vesicle protein. J. Clin. Invest. 1985; 76:1899-1903.
  7. Watt K.W.K., Lee P.-J., M’Timkulu, et al. Human prostate-specific antigen: Structural and functional similarity with serine proteases. Proc. Natl. Acad. Sci. 1986;83:3166-31670.
  8. Yousef G.M., Diamandis E.P. An overview of the kaffikrein gene families in humans and other species: Emerging candidate tumor markers. Clin. Biochem. 2003;36:443-452.
  9. Stephan C, Jung K, Diamandis E.P. et al. Prostate-specific antigen, its molecular forms, and other kaHikrein markers for detection of prostate cancer. Urology. 2002;59:208.
  10. Catalona W.J., Partin A.W., Slawin K.M., et al. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease. A prospective multicenter clinical trial. JAMA. 1998;279:1542-1547.
  11. Mikolajczyk S.D., Marker K.M., Millar L.S. et al. A truncated precursor form of prostate-specific antigen is a more specific serum marker of prostate cancer. Cancer Res. 2001;61:6958-6963.
  12. Semjonow A., Kopke T., Eltze E. et al. Pre-analytical in-vitro stability of [-2]proPSA in blood and serum. Clinical Biochemistry.2010;43:926-928.
  13. Mikolajczyk S.D., Catalona W.J., Evans C.L. et al. Proenzyme forms of prostate specific antigen in serum improve the detection of prostate cancer. Clinical Chemistry. 2004;50(6):1017-1025.
  14. Stephan C., Vincendeau S., Houlgatte A. et al. Multicenter Evaluation of [-2]Proprostate-Specific Antigen and the Prostate Health Index for Detecting Prostate Cancer. Clinical Chemistry. 2013; 59:306-314.
  15. Sokoll L.J., Wang Y., Feng Z. et al. [-2]proenzyme prostate specific antigen for prostate cancer detection: a national cancer institute early detection research network validation study. J. Urol. 2008;180: 539-543.
  16. Sokoll L.J., Sanda M.G., Feng Z. et al. A prospective, multicenter, National Cancer Institute Early Detection Research Network study of [-2]proPSA: improving prostate cancer detection and correlating with cancer aggressiveness. Cancer Epidemiol Biomarkers Prev. 2010;19:1193-1200.
  17. Rhodes T, Jacobson D.J., McGree M.E. et al. Longitudinal changes of benign prostate-specific antigen and [-2]proprostate-specific antigen in seven years in a community-based sample of men. Urology. 2012;79:655-661.
  18. Le B.V., Griffin C.R., Loeb S. et al. [-2]Proenzyme prostate specific antigen is more accurate than total and free prostate specific antigen in differentiating prostate cancer from benign disease in a prospective prostate cancer screening study. J. Urol. 2010;183:1355-1359.
  19. Catalona W.J., Partin A.W., Sanda M.G. et al. A multicenter study of [-2]Pro-Prostate specific antigen combined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to 10.0 ng/ml prostate specific antigen range. J. Urol. 2011;185:1650-1655.
  20. Guazonni G., Lazzeri M., Nava L. et al. Preoperative prostate- specific antigen isoform p2PSA and its derivates, %p2PSA and prostate health index, predict pathologic outcomes in patients undergoing radical prostatectomy for prostate cancer. Eur. Urol. 2012;61:455-466.
  21. Сидоренков А.В., Говоров А.В., Пушкарь Д.Ю. Диагностическая значимость [-2]proPSA и индекса PHI. Собственные результаты. Материалы конгресса РОУ. Саратов. С. 75-76.
  22. NCCN Clinical Practice Guidelines in Oncology. http://www.nccn. org/professionals/physician_gls/f_guidelines.asp#site.
  23. Урология. Российские клинические рекомендации. Под ред. Ю.Г. Аляева, П.В. Глыбочко, Д.Ю. Пушкаря. М., 2015. 480 с.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2015 Bionika Media